[8-K] Medifast, Inc. Reports Material Event

Rhea-AI Filing Summary

Medifast, Inc. (NYSE: MED) filed an 8-K reporting the results of its 2025 Annual Meeting held on June 18, 2025.

Equity plan expansion: Shareholders approved an amendment to the Amended and Restated 2012 Share Incentive Plan, authorizing an additional 550,000 common shares for future equity awards. The plan became effective immediately and its full text is attached as Exhibit 10.1.

Board elections: All seven incumbent directors were re-elected. Support ranged from 90.3 % (Andrea B. Thomas) to 97.2 % (Jeffrey J. Brown) of votes cast, with 2.09 million broker non-votes recorded for each nominee.

Auditor ratification: RSM US LLP was ratified as independent auditor for FY 2025 with 99.2 % of votes in favor (8,225,570 for / 39,619 against).

Say-on-pay advisory vote: Compensation for named executive officers passed but with a modest margin—3,585,469 for vs. 2,477,849 against (59.1 % support, excluding abstentions).

Plan approval vote: The amended share incentive plan itself received 5,518,075 for vs. 664,416 against (88.2 % support, excluding abstentions).

No other material transactions, earnings data, or financial statements were disclosed.

Positive

• Shareholders approved a 550,000-share increase to the 2012 Incentive Plan, giving the company additional flexibility to recruit and retain talent.
• All directors were re-elected, preserving board continuity and strategic consistency.
• Independent auditor ratified with 99% support, signaling investor confidence in financial controls.

Negative

• Say-on-pay support at 59% shows significant shareholder dissent over executive compensation.
• Additional share authorization introduces potential dilution, which some investors may view unfavorably.

Insights

Financial Analyst

TL;DR: Share count for incentives rises; all proposals pass; say-on-pay shows some dissent.

The 550k-share increase expands Medifast’s ability to grant equity awards, a common retention tool for direct-selling firms where field leadership incentives are key. Board and auditor proposals sailed through with 90–99 % support, signaling broad governance stability. However, only 59 % of votes favored executive pay—well below the typical 90 % peer average—highlighting investor concern over recent compensation structure or performance metrics. While the added share pool is small (≈4 % of FY-end basic shares outstanding), it introduces incremental dilution investors will watch. Overall impact is modestly positive for strategic flexibility but tempered by compensation sentiment.

Corporate Governance Expert

TL;DR: Governance status quo retained; compensation support soft, but equity plan approved comfortably.

Re-election of all directors and near-unanimous auditor ratification confirm shareholder confidence in board oversight. The Amended 2012 Plan’s 88 % approval indicates investors accept modest dilution to sustain talent alignment. Yet the 41 % opposition to say-on-pay is a yellow flag: ISS and Glass Lewis generally flag anything below 70 % as requiring responsive board engagement. Expect follow-up disclosure in next proxy detailing outreach and potential pay structure adjustments. No emerging-growth exemptions claimed, and required exhibits were properly filed, evidencing procedural compliance.

0000910329FALSE00009103292025-06-182025-06-180000910329exch:XNYS2025-06-182025-06-18

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_____________________________________

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 18, 2025

MEDIFAST, INC.

(Exact name of registrant as specified in its charter)

Delaware			001-31573			13-3714405
(State or other jurisdiction of incorporation)			(Commission File Number)			(I.R.S. Employer Identification No.)

100 International Drive, Baltimore, Maryland 21202

(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: (410) 581-8042

N/A

(Former Name or Former Address, if Changed Since Last Report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol			Name of each exchange on which registered
Common Stock, par value $0.001 per share			MED			New York Stock Exchange

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company			☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.			o

Item 5.02.     Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;                         Compensatory Arrangements of Certain Officers.

On June 18, 2025, as described below under Item 5.07 of this Current Report on Form 8-K, the stockholders of Medifast, Inc. (the "Company") approved an amendment to the Amended and Restated 2012 Share Incentive Plan (the "2012 Plan") primarily to increase the number of shares of the Company's common stock authorized for issuance under the 2012 Plan by 550,000 shares (as amended, the “Amended 2012 Plan”) at the Company’s 2025 annual meeting of stockholders (the "Annual Meeting"). The Amended 2012 Plan became effective immediately upon stockholder approval at the Annual Meeting.

A description of the material terms of the Amended 2012 Plan is included in the Company’s definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 29, 2025 (the “Proxy Statement”), under the section captioned "PROPOSAL 4 - APPROVAL OF THE AMENDED AND RESTATED 2012 SHARE INCENTIVE PLAN," which description is incorporated herein by reference.

The descriptions of the Amended 2012 Plan contained herein and in the Proxy Statement are not complete and are qualified in their entireties by the full text of the Amended 2012 Plan, a copy of which is filed hereto as Exhibit 10.1 and incorporated herein by reference.

Item 5.07.    Submission of Matters to a Vote of Security Holders.

At the Annual Meeting, the stockholders voted on the following four proposals and cast their votes as described below.

(i) The number of shares voted and broker non-votes for the directors nominated for re-election to the Board are set forth below.

Director Name			For			Against			Abstained			Broker Non-Votes
Jeffrey J. Brown			6,046,608			132,731			12,471			2,093,807
Daniel R. Chard			5,961,959			134,118			95,733			2,093,807
Elizabeth A. Geary			5,845,990			331,620			14,200			2,093,807
Michael A. Hoer			6,040,159			139,195			12,456			2,093,807
Scott Schlackman			6,039,147			139,910			12,753			2,093,807
Andrea B. Thomas			5,778,243			401,298			12,269			2,093,807
Ming Xian			5,779,065			398,124			14,621			2,093,807

Accordingly, each of the individuals listed above was re-elected to the Company’s Board of Directors, each to hold office until the Company’s next annual meeting of stockholders and until his or her successor is duly elected and qualified, or until his or her earlier death, resignation or removal.

(ii) The stockholders voted on a proposal to ratify the appointment of RSM US LLP as the Company’s Independent Registered Public Accounting Firm for the fiscal year ending December 31, 2025.

The proposal was approved by a vote of stockholders as follows:

For:			8,225,570
Against:			39,619
Abstained:			20,428

(iii) The stockholders voted on a proposal to approve, on an advisory basis, the compensation of the Company’s named executive officers as set forth in the proxy statement for the Annual Meeting.

The proposal was approved by a vote of the stockholders as follows:

For:			3,585,469
Against:			2,477,849
Abstained:			128,492
Broker Non-Votes:			2,093,807

(iv) The stockholders voted on a proposal to approve the Amended 2012 Plan.

The proposal was approved by a vote of the stockholders as follows:

For:			5,518,075
Against:			664,416
Abstained:			9,319
Broker Non-Votes:			2,093,807

Item 9.01.    Financial Statements and Exhibits.

(d)			Exhibits.
			10.1			Amended and Restated 2012 Share Incentive Plan
			104.1			Cover Page Interactive Data File (embedded within the Inline XBRL Document)

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			MEDIFAST, INC.
			By:			/s/ James P. Maloney
						James P. Maloney
						Chief Financial Officer
Dated: June 20, 2025

FAQ

What did Medifast (MED) shareholders approve regarding the 2012 Share Incentive Plan?

They added 550,000 common shares to the plan, effective June 18 2025.

How much support did the say-on-pay proposal receive at Medifast’s 2025 AGM?

The advisory vote passed with 3,585,469 for vs. 2,477,849 against (≈59 % support).

Were all Medifast directors re-elected in 2025?

Yes. All seven nominees received between 90 % and 97 % of votes cast and will serve until the next annual meeting.

Which firm will audit Medifast for fiscal year 2025?

Shareholders ratified RSM US LLP with 8,225,570 votes in favor.

Does the 8-K disclose any earnings or acquisition information?

No. The filing focuses on shareholder meeting results and the amended incentive plan; it contains no earnings or M&A data.